- Home
- IVVD vs INFU Comparison
IVVD vs INFU Comparison
Compare IVVD & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | INFU |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | 122 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.9M | 197.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IVVD | INFU |
|---|---|---|
| Price | $0.77 | $12.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $8.75 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 3.9M | 96.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.02 | ★ 181.82 |
| EPS | N/A | ★ 0.20 |
| Revenue | $53,426,000.00 | ★ $143,436,000.00 |
| Revenue This Year | $61.57 | $3.20 |
| Revenue Next Year | $41.42 | $7.31 |
| P/E Ratio | ★ N/A | $62.40 |
| Revenue Growth | ★ 110.47 | 6.36 |
| 52 Week Low | $0.53 | $7.29 |
| 52 Week High | $3.07 | $12.97 |
Technical Indicators
Market Signals| Indicator | IVVD | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 59.37 |
| Support Level | $0.71 | $11.79 |
| Resistance Level | $1.02 | $12.47 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 12.71 | 56.53 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.